Holocene Advisors LP Has $57.82 Million Position in Evolent Health, Inc. (NYSE:EVH)

Holocene Advisors LP lessened its stake in shares of Evolent Health, Inc. (NYSE:EVH) by 33.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,044,606 shares of the technology company’s stock after selling 1,031,121 shares during the period. Holocene Advisors LP owned 1.76% of Evolent Health worth $57,821,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of EVH. Point72 Asia Singapore Pte. Ltd. raised its holdings in Evolent Health by 2,471.9% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 6,507 shares of the technology company’s stock worth $184,000 after buying an additional 6,254 shares during the last quarter. Bellevue Group AG raised its holdings in Evolent Health by 59.9% during the third quarter. Bellevue Group AG now owns 2,670,050 shares of the technology company’s stock worth $75,509,000 after buying an additional 1,000,215 shares during the last quarter. Eventide Asset Management LLC raised its holdings in Evolent Health by 1.7% during the third quarter. Eventide Asset Management LLC now owns 3,804,104 shares of the technology company’s stock worth $107,580,000 after buying an additional 64,985 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Evolent Health by 150.4% during the third quarter. BNP Paribas Financial Markets now owns 25,469 shares of the technology company’s stock worth $720,000 after buying an additional 15,299 shares during the last quarter. Finally, Qsemble Capital Management LP acquired a new position in Evolent Health during the third quarter worth $829,000.

Analysts Set New Price Targets

EVH has been the topic of several research reports. JPMorgan Chase & Co. lowered their price objective on shares of Evolent Health from $45.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday, November 22nd. Barclays lowered their price objective on shares of Evolent Health from $39.00 to $19.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. KeyCorp started coverage on shares of Evolent Health in a report on Friday, October 11th. They issued an “overweight” rating and a $35.00 target price for the company. Truist Financial reiterated a “buy” rating and issued a $33.00 target price on shares of Evolent Health in a report on Tuesday, August 27th. Finally, JMP Securities lowered their target price on shares of Evolent Health from $34.00 to $31.00 and set a “market outperform” rating for the company in a report on Friday, August 9th. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $25.90.

Evolent Health Stock Performance

EVH opened at $12.72 on Tuesday. The firm has a 50-day moving average of $21.47 and a 200 day moving average of $23.33. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. Evolent Health, Inc. has a fifty-two week low of $11.17 and a fifty-two week high of $35.00.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.